surmount-1 trial tirzepatide weight loss non-diabetic SURMOUNT‐1 study design. This is a phase 3, multicenter, randomized, SURMOUNT 1 // Three-Year Obesty

Instead of visiting a clinic in person, patients connect with licensed medical professionals via online platforms for consultations, prescriptions, and ongoing treatment

This prescription medication offers significant benefits for patients who have struggled with blood sugar control and weight management, providing a dual approach to improving overall health

At a glance 150mg and 300mg tablets

Sunny Hostin, 57 The View co-host Sunny Hostin first opened up about her GLP-1 use during a March 2024 episode of the morning talk show, according to People magazine

Among patients who stopped taking tirzepatide, 31.0% doubled their weight loss after two years, 15.2% lost some additional weight, and 9.0% maintained their initial loss, with 55.2% in total maintaining or losing more weight